- $67.20m
- $7.17m
Annual income statement for IO Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 10.1 | 41.2 | 71.4 | 91.4 | 95.2 |
| Operating Profit | -10.1 | -41.2 | -71.4 | -91.4 | -95.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -12 | -67.8 | -70.2 | -85.2 | -94 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -12 | -67.9 | -71.5 | -86.1 | -95.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -12 | -67.9 | -71.5 | -86.1 | -95.5 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -14.6 | -75 | -71.5 | -86.1 | -95.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.526 | -2.6 | -2.48 | -1.98 | -1.45 |